retatrutide trial weight loss data just delivered the most powerful ever recorded in a Phase 3 obesity trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds The results everyone has been

SGLT2 inhibitors were administered for a median of 21 weeks, and 12 patients were diagnosed with severe OSA

This does not mean the clinicians are unqualifiedbut it does mean that many online patients are not receiving care from those with formal expertise in obesity care

Those are not small differences between doses

Columbia Center for Metabolic and Weight Loss Surgery

They may also need to show that you meet certain criteria, such as having a body mass index (BMI) of 27 or higher, or having a weight-related health condition, such as : High cholesterol High blood pressure Type 2 diabetes Some drugs that are prescribed off-label for weight loss such as Ozempic or Mounjaro are FDA-approved for people with type 2 diabetes